Annual report
2269.TEDINET S100PUVS
Period2018-04-01 → 2019-03-31
Filed2022-12-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100G7UL.
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.25T | 2018-04-01 → 2019-03-31 | Cons. | Net sales |
| Revenue | ¥1.24T | 2017-04-01 → 2018-03-31 | Cons. | Net sales |
| Revenue | ¥1.24T | 2016-04-01 → 2017-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.22T | 2015-04-01 → 2016-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.16T | 2014-04-01 → 2015-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥98.4bn | 2018-04-01 → 2019-03-31 | Cons. | Operating income |
| Operating income | ¥94.7bn | 2017-04-01 → 2018-03-31 | Cons. | Operating income |
| Ordinary income | ¥99.7bn | 2018-04-01 → 2019-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥95.9bn | 2017-04-01 → 2018-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥88.8bn | 2016-04-01 → 2017-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥81.8bn | 2015-04-01 → 2016-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥53.6bn | 2014-04-01 → 2015-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥94.6bn | 2018-04-01 → 2019-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥91.1bn | 2017-04-01 → 2018-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥61.9bn | 2018-04-01 → 2019-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥61.3bn | 2017-04-01 → 2018-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥60.8bn | 2016-04-01 → 2017-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥62.6bn | 2015-04-01 → 2016-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥30.9bn | 2014-04-01 → 2015-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥63.6bn | 2018-04-01 → 2019-03-31 | Cons. | Profit loss |
| Net income | ¥62.0bn | 2017-04-01 → 2018-03-31 | Cons. | Profit loss |
| Total assets | ¥1.00T | at 2019-03-31 | Cons. | Assets |
| Total assets | ¥925.2bn | at 2018-03-31 | Cons. | Assets |
| Total assets | ¥883.9bn | at 2017-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥856.1bn | at 2016-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥877.4bn | at 2015-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥443.5bn | at 2019-03-31 | Cons. | Liabilities |
| Total liabilities | ¥430.1bn | at 2018-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥560.6bn | at 2019-03-31 | Cons. | Net assets |
| Net assets / equity | ¥495.2bn | at 2018-03-31 | Cons. | Net assets |
| Net assets / equity | ¥457.2bn | at 2017-03-31d | Cons. | Net assets |
| Net assets / equity | ¥419.2bn | at 2016-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥380.3bn | at 2015-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥25.4bn | at 2019-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.6bn | at 2018-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥24.5bn | at 2019-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2018-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.6bn | at 2017-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.5bn | at 2016-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥21.9bn | at 2015-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥112.1bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥108.8bn | 2017-04-01 → 2018-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥81.9bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥105.2bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥86.5bn | 2014-04-01 → 2015-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥100.2bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥64.4bn | 2017-04-01 → 2018-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥44.3bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.8bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥92.8bn | 2014-04-01 → 2015-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥14.0bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥40.1bn | 2017-04-01 → 2018-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥46.5bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥85.1bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥6.8bn | 2014-04-01 → 2015-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥426.61 | 2018-04-01 → 2019-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥422.15 | 2017-04-01 → 2018-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥413.11 | 2016-04-01 → 2017-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥425.06 | 2015-04-01 → 2016-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.79 | 2014-04-01 → 2015-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,635.79 | at 2019-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,360.7 | at 2018-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,064.91 | at 2017-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,777.28 | at 2016-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,515.26 | at 2015-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 52.5% | at 2019-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2018-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.8% | at 2017-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.8% | at 2016-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.2% | at 2015-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.2% | 2018-04-01 → 2019-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.1% | 2017-04-01 → 2018-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2016-04-01 → 2017-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2015-04-01 → 2016-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2014-04-01 → 2015-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 17,608 | at 2019-03-31 | Cons. | Number of employees |
| Employees | 16,296 | at 2018-03-31 | Cons. | Number of employees |
| Employees | 16,726 | at 2017-03-31d | Cons. | Number of employees |
| Employees | 16,456 | at 2016-03-31d | Cons. | Number of employees |
| Employees | 16,559 | at 2015-03-31d | Cons. | Number of employees |
| Revenue | ¥21.6bn | 2018-04-01 → 2019-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥19.6bn | 2017-04-01 → 2018-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.3bn | 2016-04-01 → 2017-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥9.7bn | 2015-04-01 → 2016-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥9.3bn | 2014-04-01 → 2015-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥19.3bn | 2018-04-01 → 2019-03-31 | Standalone | Operating income |
| Operating income | ¥17.5bn | 2017-04-01 → 2018-03-31 | Standalone | Operating income |
| Ordinary income | ¥19.9bn | 2018-04-01 → 2019-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.0bn | 2017-04-01 → 2018-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.2bn | 2016-04-01 → 2017-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.9bn | 2015-04-01 → 2016-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.5bn | 2014-04-01 → 2015-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥19.8bn | 2018-04-01 → 2019-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.0bn | 2017-04-01 → 2018-03-31 | Standalone | Income before income taxes |
| Net income | ¥19.8bn | 2018-04-01 → 2019-03-31 | Standalone | Profit loss |
| Net income | ¥18.0bn | 2017-04-01 → 2018-03-31 | Standalone | Profit loss |
| Net income | ¥16.0bn | 2016-04-01 → 2017-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.0bn | 2015-04-01 → 2016-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.3bn | 2014-04-01 → 2015-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥385.7bn | at 2019-03-31 | Standalone | Assets |
| Total assets | ¥386.8bn | at 2018-03-31 | Standalone | Assets |
| Total assets | ¥421.2bn | at 2017-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥432.7bn | at 2016-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥489.7bn | at 2015-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥119.8bn | at 2019-03-31 | Standalone | Liabilities |
| Total liabilities | ¥120.5bn | at 2018-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥265.9bn | at 2019-03-31 | Standalone | Net assets |
| Net assets / equity | ¥266.3bn | at 2018-03-31 | Standalone | Net assets |
| Net assets / equity | ¥276.5bn | at 2017-03-31d | Standalone | Net assets |
| Net assets / equity | ¥283.6bn | at 2016-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥273.7bn | at 2015-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.3bn | at 2019-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.1bn | at 2018-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥136.71 | 2018-04-01 → 2019-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥124 | 2017-04-01 → 2018-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.85 | 2016-04-01 → 2017-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥129.14 | 2015-04-01 → 2016-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.47 | 2014-04-01 → 2015-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥140 | 2018-04-01 → 2019-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2017-04-01 → 2018-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2016-04-01 → 2017-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2015-04-01 → 2016-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2014-04-01 → 2015-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,833.11 | at 2019-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,836.25 | at 2018-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,887.79 | at 2017-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,926.48 | at 2016-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,859.04 | at 2015-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 68.9% | at 2019-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.8% | at 2018-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2017-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2016-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.9% | at 2015-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.5% | 2018-04-01 → 2019-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2017-04-01 → 2018-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2016-04-01 → 2017-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2015-04-01 → 2016-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2014-04-01 → 2015-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 152,683,000 | at 2019-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2018-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2017-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2016-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 76,341,000 | at 2015-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 34 | at 2019-03-31 | Standalone | Number of employees |
| Employees | 35 | at 2018-03-31 | Standalone | Number of employees |
| Employees | 36 | at 2017-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2016-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2015-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2018-04-01 → 2019-03-31 | ¥175m |
| Reconciling Itemsreconciling | depreciation | 2018-04-01 → 2019-03-31 | ¥302m |
| Reconciling Itemsreconciling | revenue | 2018-04-01 → 2019-03-31 | −¥946m |
| Reconciling Itemsreconciling | revenue intersegment | 2018-04-01 → 2019-03-31 | −¥946m |
| Reconciling Itemsreconciling | segment assets | at 2019-03-31 | ¥30.4bn |
| Reconciling Itemsreconciling | segment profit | 2018-04-01 → 2019-03-31 | −¥624m |
| Foodreportable segment | capex | 2018-04-01 → 2019-03-31 | ¥60.1bn |
| Foodreportable segment | depreciation | 2018-04-01 → 2019-03-31 | ¥34.5bn |
| Foodreportable segment | employees | at 2019-03-31 | 10815 pure |
| Foodreportable segment | revenue | 2018-04-01 → 2019-03-31 | ¥1.06T |
| Foodreportable segment | revenue external | 2018-04-01 → 2019-03-31 | ¥1.06T |
| Foodreportable segment | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥530m |
| Foodreportable segment | segment assets | at 2019-03-31 | ¥690.9bn |
| Foodreportable segment | segment profit | 2018-04-01 → 2019-03-31 | ¥84.8bn |
| Pharmaceuticalsreportable segment | capex | 2018-04-01 → 2019-03-31 | ¥10.9bn |
| Pharmaceuticalsreportable segment | depreciation | 2018-04-01 → 2019-03-31 | ¥8.2bn |
| Pharmaceuticalsreportable segment | employees | at 2019-03-31 | 6755 pure |
| Pharmaceuticalsreportable segment | revenue | 2018-04-01 → 2019-03-31 | ¥198.7bn |
| Pharmaceuticalsreportable segment | revenue external | 2018-04-01 → 2019-03-31 | ¥198.3bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥415m |
| Pharmaceuticalsreportable segment | segment assets | at 2019-03-31 | ¥282.9bn |
| Pharmaceuticalsreportable segment | segment profit | 2018-04-01 → 2019-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2018-04-01 → 2019-03-31 | ¥71.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2018-04-01 → 2019-03-31 | ¥42.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2018-04-01 → 2019-03-31 | ¥1.26T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2018-04-01 → 2019-03-31 | ¥1.25T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥946m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2019-03-31 | ¥973.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2018-04-01 → 2019-03-31 | ¥99.0bn |
| Reconciling Itemsreconciling | capex | 2017-04-01 → 2018-03-31 | ¥37m |
| Reconciling Itemsreconciling | depreciation | 2017-04-01 → 2018-03-31 | ¥315m |
| Reconciling Itemsreconciling | revenue | 2017-04-01 → 2018-03-31 | −¥1.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2017-04-01 → 2018-03-31 | −¥1.3bn |
| Reconciling Itemsreconciling | segment assets | at 2018-03-31 | ¥53.4bn |
| Reconciling Itemsreconciling | segment profit | 2017-04-01 → 2018-03-31 | −¥541m |
| Foodreportable segment | capex | 2017-04-01 → 2018-03-31 | ¥66.2bn |
| Foodreportable segment | depreciation | 2017-04-01 → 2018-03-31 | ¥40.2bn |
| Foodreportable segment | revenue | 2017-04-01 → 2018-03-31 | ¥1.07T |
| Foodreportable segment | revenue external | 2017-04-01 → 2018-03-31 | ¥1.07T |
| Foodreportable segment | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥577m |
| Foodreportable segment | segment assets | at 2018-03-31 | ¥659.2bn |
| Foodreportable segment | segment profit | 2017-04-01 → 2018-03-31 | ¥84.2bn |
| Pharmaceuticalsreportable segment | capex | 2017-04-01 → 2018-03-31 | ¥8.4bn |
| Pharmaceuticalsreportable segment | depreciation | 2017-04-01 → 2018-03-31 | ¥6.0bn |
| Pharmaceuticalsreportable segment | revenue | 2017-04-01 → 2018-03-31 | ¥168.5bn |
| Pharmaceuticalsreportable segment | revenue external | 2017-04-01 → 2018-03-31 | ¥167.8bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥683m |
| Pharmaceuticalsreportable segment | segment assets | at 2018-03-31 | ¥212.7bn |
| Pharmaceuticalsreportable segment | segment profit | 2017-04-01 → 2018-03-31 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2017-04-01 → 2018-03-31 | ¥74.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2017-04-01 → 2018-03-31 | ¥46.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2017-04-01 → 2018-03-31 | ¥1.24T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2017-04-01 → 2018-03-31 | ¥1.24T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2018-03-31 | ¥871.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2017-04-01 → 2018-03-31 | ¥95.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,795
| Item | Context | Value | Unit |
|---|---|---|---|
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.471 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 10815 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 6837 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 6755 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 2870 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 38 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 16 | |
| Number of employees | CurrentYearInstant | 17608 | |
| Average number of temporary workers | CurrentYearInstant | 9723 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 34 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 4 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 43.1 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 20.1 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 9965000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 34 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 4 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 34 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 4 | |
| Research and development expenses research and development activities | CurrentYearDuration | 29182000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 12712000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 16470000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 66953000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 57186000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 9766000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 152683400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 152683400 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 152683400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 152683400 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 133 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 36 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 657 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 663 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 64754 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 66270 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 626592 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 26653 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 150893 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 362090 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 52 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 353008 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 1519288 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 754600 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.4124 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0175 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.0993 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |